摘要
目的 :比较生长抑素14肽 (施他宁 )与8肽衍生物奥曲肽 (善宁 )在食管静脉曲张破裂患者大出血中的疗效、不良反应及成本 -效果比。方法 :运用药物经济学成本 -效果分析方法 ,对56例分别应用施他宁和善宁治疗肝硬化食管静脉曲张破裂大出血患者的疗效及成本进行评价。结果 :两组疗程结束时 ,施他宁和善宁的疗效相近 (P>0 05) ,有效率分别为89 29 %和82 14 % ,平均止血时间分别为 (15 67±7 34)小时和 (17 22±9 38)小时 ,成本 -效果比分别为51 54和65 94。疗程总费用善宁组比施他宁组多出814 34元 ,成本 -效果比显示疗程总费用有效率每升高1个百分点所需增加的费用 ,施他宁组为51 54元 ,善宁组为65 94元 ,组间相差14 4元。结论 :应用施他宁相对低廉 ,成本 -效果比优于善宁。两组的不良反应无显著性差异。
OBJECTIVE:To compare the therapeutic effects,adverse reactions and the costs between Somatostatin and Octreotide in treatment of esophageal variceal hemorrhage.METHODS:Using pharmacoeconomic cost-effectiveness analysis,Somatostatin was compared with Octreotide in treatment of 56 cases(divided into two groups) of liver cirrhosis with esophageal variceal hemorrhage.RESULTS:At the ending of the course,the effective rates of two groups were similar(P>0.05).The effective rates of Somatostatin and Octreotide were 89.29% and 82.14%;the time averages for hemostasia were (15.67±7.34)hrs and (17.22±9.38)hrs respectively;the cost-effectiveness ratios were 51.54 and 65.94 respectively.For all-in cost of a therapeutic course,Octreotide group exceeded 814.34 yuans compared to Somatostatin group.The cost-effective ratios showed that the all-in costs of Somatostatin and Octreotide groups were 51.54 yuans and 65.94 yuans respectively in increase of 1% of effective rate with a difference of 14.4 yuans.CONCLUSION:Somatostatin is cheaper in cost and better in cost-effective ratio in comparison with Octreotide.
出处
《中国药房》
CAS
CSCD
2003年第1期27-28,共2页
China Pharmacy